Hematopoietic cancer is a malignant transformation in immune system cells. Hematopoietic cancer is characterized by the cells that are expressed, so it is usually difficult to distinguish its heterogeneities in the hematopoiesis process. Traditional approaches for cancer subtyping use statistical techniques. Furthermore, due to the overfitting problem of small samples, in case of a minor cancer, it does not have enough sample material for building a classification model. Therefore, we propose not only to build a classification model for five major subtypes using two kinds of losses, namely reconstruction loss and classification loss, but also to extract suitable features using a deep autoencoder. Furthermore, for considering the data imbalance problem, we apply an oversampling algorithm, the synthetic minority oversampling technique (SMOTE). For validation of our proposed autoencoder-based feature extraction approach for hematopoietic cancer subtype classification, we compared other traditional feature selection algorithms (principal component analysis, non-negative matrix factorization) and classification algorithms with the SMOTE oversampling approach. Additionally, we used the Shapley Additive exPlanations (SHAP) interpretation technique in our model to explain the important gene/protein for hematopoietic cancer subtype classification. Furthermore, we compared five widely used classification algorithms, including logistic regression, random forest, k-nearest neighbor, artificial neural network and support vector machine. The results of autoencoder-based feature extraction approaches showed good performance, and the best result was the SMOTE oversampling-applied support vector machine algorithm consider both focal loss and reconstruction loss as the loss function for autoencoder (AE) feature selection approach, which produced 97.01% accuracy, 92.60% recall, 99.52% specificity, 93.54% F1-measure, 97.87% G-mean and 95.46% index of balanced accuracy as subtype classification performance measures.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926954 | PMC |
http://dx.doi.org/10.3390/ijerph18042197 | DOI Listing |
J Clin Immunol
December 2024
Department of Pediatrics, Division of Pediatric Hematology Oncology and Bone Marrow Transplantation, King Hussein Cancer Center, 202 Queen Rania Street, Amman, 11941, Jordan.
Inborn errors of immunity (IEI) are a heterogenous group of rare monogenic disorders that affect innate or adaptive immunity, resulting in susceptibility to life-threatening infections and autoimmunity. Allogeneic hematopoietic cell transplantation (HCT) is a valuable curative option for children with IEI. We conducted a retrospective single-center study on the outcome of HCT in children with IEI.
View Article and Find Full Text PDFHematol Rep
December 2024
Oncohematology Division, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Richter syndrome (RS) represents a major unmet need in the lymphoma field, being refractory to chemoimmunotherapy and targeted agents. The BCL-2 inhibitor venetoclax in combination with dose-adjusted EPOCH-R chemoimmunotherapy showed promising efficacy in patients affected by RS. However, responses were not durable, suggesting the need for further treatment optimization.
View Article and Find Full Text PDFHematol Rep
December 2024
Department of Hematology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Acute myeloid leukemia (AML) is a form of cancer originating from precursor cells within the bone marrow. Elderly patients with acute leukemia require a personalized approach, considering age, performance status, and comorbidities, to determine suitability for intensive treatment. We studied the results of intense chemotherapy in 46 elderly, fit individuals with AML at a cancer center in Romania from January 2017 to December 2023.
View Article and Find Full Text PDFCurr Oncol
November 2024
Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada.
In the evaluation of a patient's primary hematologic malignancy, positron emission tomography/computed tomography (PET/CT) imaging may incidentally detect a concerning abnormality suggestive of a second concurrent cancer. Despite accounting for nearly 10% of all cancers diagnosed in Canada, there has yet to be a systematic review focused on the prevalence and significance of these incidental PET/CT findings in the context of primary hematologic malignancies. As such, a systematic search strategy was employed on MEDLINE and Embase to document the prevalence and clinical significance of incidental PET/CT findings suggestive of a second concurrent cancer detected in patients evaluated for their primary hematologic malignancy.
View Article and Find Full Text PDFLeuk Lymphoma
December 2024
Blood Cancer Institute, Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, USA.
Overactivation of the Transforming Growth Factor Beta (TGF-β) pathway is implicated in the pathogenesis of cytopenias in Myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML). IOA-359 and IOA-360 are potent small molecule inhibitors of the TGF-beta Receptor type I kinase (TGF-βRI, also referred to as ALK5, activin receptor-like kinase 5) that abrogate SMAD phosphorylation in hematopoietic cell lines. Both inhibitors were able to inhibit TGF-β mediated gene transcription at specific doses.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!